Abstract: A novel method for treating a human female is disclosed comprising the step of exposing the nasal region of said female to at least a portion of the axillary secretions of a human male. This exposure is preferably continued in amounts and for a duration which are effective to significantly alter an endocrine related characteristic, such as the menstrual cycle length, of that female. In particular, the portions of male axillary secretions to be exposed to the female preferably comprise one or more compounds such as androstenol, dehydroepiandrosterone, and/or a compound or compounds exhibiting a burnt heavy axiallary-like odor which elutes at about 50 minutes as shown on the FID response curve of FIG. 3B. Studies show that pooled male donor secretions are effective to alter aberrant menstrual cycles, particularly those exhibiting luteal phase defects such that they become presumptively fertile menstrual cycles having durations of about 29.5.+-.3 days.

Abstract: A method for preparing polypeptides in bacteria with an alanine rather than a methionine at the N-terminus. The DNA sequence expressed has an alanine codon immediately following from at least one methionine codon, and allows for the expression of polypeptides having the amino acid sequence essentially the same as such naturally occurring eucaryotic protein as various bovine and porcine somatotropin species. In another important embodiment, the invention provides a class of compositions comprising certain valine-containing somatropin species which increase milk production in lactating mammals to a significantly greater extent than otherwise-identical leucine somatotropin species.

Abstract: Human growth hormone is used for the treatment of individuals who are intoxicated with poisonous substances of the type which is degraded in the liver by microsomal enzymes, such as hexobarbiturates or alcohol. Unit dose preparations containing a pharmachologically active dose of human growth hormone is used for treating intoxicated individuals.

Abstract: Human Growth Hormone-Releasing Factor (hGRF) analogs having the sequence [Pro.sup.0, X.sup.15, Y.sup.27 ]-hGRF(1-A)-B, wherein X is selected from the group consisting of Ala and Gly, Y is selected from the group consisting of Ile, Leu, Val, Nle and Met, A has a value from 29-44, and B is NH.sub.2, OH or COOH are synthesized and administered to animals to stimulate the release of Growth Hormone (GH).

Abstract: An antimicrobial composition comprises a clathrate compound containing a water-soluble microbicide, and a dispersion medium.For example, the composition may comprise of a clathrate compound containing a water-soluble microbicide and having a particle size of 200 mesh at maximum, said clathrate compound being formed of 5-chloro-2-methyl-4-isothiazoline-3-one and at least one polymolecular host compound selected from the group consisting of 1, 1-di (2,4-dimethylphenyl)-2-propyne-1-ol; 1,1,6,6-tetra(2,4-dimethylphenyl)-2,4-hexadiyne-1,6-diol; 1,1-bis(4-hydroxyphenyl)cyclohexane; N,N,N',N'-tetra(cyclohexyl)-[1,1'biphenyl]-2,2'-dicarboxyamide; 2,2'-methylenebis(4-chlorophenol), deoxycholic acid; and 2,5-di-tert-butylhydroquinone and a dispersion medium.

Abstract: Antagonists to basic fibroblast growth factor, a 146 amino acid residue polypeptide, are produced. These antagonists are generally between 4 and 45 residues in length and are characterized by their ability to interact with the FGF receptor and/or inhibit and therefore modulate endothelial and other cell growth. One group of these antagonists includes the four residue sequence which forms basic FGF(36-39), namely Pro-Asp-Gly-Arg. Another of these antagonists includes the sequence of bovine basic FGF(106-115), namely Tyr-Arg-Ser-Arg-Lys-Tyr-Ser-Ser-Trp-Tyr. These peptides are also antagonistic to acidic FGF and other members of the family of FGF peptides. They are effective to combat FGF-promoted mitosis in melanomas and the like.

Abstract: The growth of milk-producing mammary parenchyma in a mammal can be significantly enhanced by administering to the mammal by intramammary infusion a substance having a mitogenic effect on mammary epithelial cells in said mammal. Good growth enhancement can be achieved using very small quantities of such substances, and in relatively short periods of time.

Abstract: Treatment of basic fibroblast growth factor (bFGF) with organic disulfides, preferably glutathione disulfide, or with inorganic compounds of similar function results in a bFGF composition of enhanced stability and resistance to multimerization. The resulting stabilized form mimics the chromatographic behavior of bFGF as isolated from bovine pituitary.

Abstract: The growth of milk-producing mammary parenchyma in a mammal can be significantly enhanced by administering to the mammal by intramammary infusion a substance having a mitogenic effect on mammary epithelial cells in said mammal. Good growth enhancement can be achieved using very small quantities of such substances, and in relatively short periods of time.

Abstract: Proteins having substantially the same biological activity as PDGF are provided. In one aspect, a protein homodimer having two polypeptide chains is disclosed, each of the chains being a mosaic of amino acid sequences substantially identical to portions of the A- and B-chains of PDGF, the protein being chemotactic or mitogenic for fibroblasts. Therapeutic compositions comprising such proteins in combination with a physiologically acceptable carrier or diluent are also provided. Such therapeutic compositions may be used within methods for enhancing the wound-healing process in warm-blooded animals.

Abstract: A method is disclosed for enhancing growth of a mammal by administration of a combination of effective amounts of IGF-I and GH so as to enhance the growth of the mammal over the enhancement in growth achieved using either IGF-I or GH alone in an amount equal to that used for either IGF-I or GH, respectively, in the combination. Preferably, the mammal is a child, the IGF-I is native-sequence, mature human IGF-I or human brain IGF-I, and the GH is native-sequence, mature human GH with or without a terminal methionine. In another preferred embodiment, the mammal is a non-human animal of economic importance such as a cow or pig.

Abstract: Homogeneous K-FGF and a process for its production are provided. Also provided are pharmaceutical compositions for use in treating soft tissue injuries and musculo-skeletal disorders in mammals and methods of treatment. The purification of the bacterially produced K-FGF comprises reduction of a salt solution containing K-FGF to effect the precipitation of the product.

Abstract: A method for promoting bone, periodontium or ligament growth of a mammal comprising applying to the bone periodontium or ligament a growth-promoting amount of a composition comprising a partially purified or purified polypeptide growth factor.

Abstract: The invention is a method of treating endotoxic shock in a mammal which comprises administering to the mammal a therapeutically effective amount of an antagonist to Platelet Activating Factor in combination with a therapeutically effective amount of one or more monoclonal or polyclonal antibodies directed toward either Tumor Necrosis Factor .alpha., Interleukin-1.beta., Gamma Interferon, or bacterial cell wall lipopolysaccharides.

Abstract: Porcine somatotropin (pST) and dietary lysine are administered in combination in dosages of from about 1-20 mg/swine/day pST and from about 0.9-1.6% by weight dietary lysine to synergistically promote growth, improve weight gain and increase feed utilization efficiency in swine. Administration of the compounds is conveniently accomplished by (1) administering porcine somatotropin (pST) to swine using conventional methods such as injections or implants and (2) feeding the swine a feed composition containing the lysine.

Abstract: Conjugates comprising a therapeutically effective proteinaceous active moiety linked to an albumin moiety which exhibit enhanced serum half-life and stability properties are disclosed. The conjugates may additionally comprise targeting moieties to facilitate selective localization of the active moiety at a target site. Conjugates of the present invention comprising an albumin moiety additionally exhibit reduced toxicity, yet maintain a high degree of selectivity and potency.

Abstract: The present disclosure relates to a new lymphokine molecule, referred to as Monocyte Cytotoxicity Inducing Factor (MCF), and its use as in cancer and other types of therapy. The disclosure further relates to the development of novel Sezary cell hybridomas which secrete MCF and thereby provide a ready source for MCF isolation and purification. Sezary'Syndrome is a leukemic proliferation of OKT4+ lymphocytes. Sezary cells were isolated by differential centrifugation and fused to CEM.8azarC, an HGPRTase lacking clone of CEM. The hybrid cells were studied for their ability to produce soluble mediators of human monocyte cytotoxicity. The product of a single clone, FtF3, which bore the surface phenotype of Sezary cells, was characterized. Monocyte cytotoxicity inducing factor was found to be stable at pH 2 for one hour, unlike interferon-gamma, and was found to be more heat stable as well.

Abstract: The present invention relates to a method for the removal of lipids and cholesterol from protein materials comprising the steps of (a) treating the protein with an extraction mixture comprising a lower alcohol, water and an acid, in concentrations selected to extract cholesterol and lipids from the protein, and (b) removing the extraction mixture from the protein.

Abstract: A method of purifying PAI-1 from a biological fluid source, e.g. conditioned media of Hep G2 or HT 1020 cells, containing PAI-1 is disclosed, which comprises subjecting the biological fluid to a modified urokinase affinity absorbent, e.g. anhydrourokinase ligand bound to a CNBr-activated agarose gel or urokinase mutated at amino acid position 356 from Ser to Gly and bound to the gel, and then eluting PAI-1 from said affinity absorbent. A method of stabilizing and/or activating PAI-1 is also disclosed, which comprises complexing PAI-1 with vitronectin.

Abstract: A composition and method for nasal administration of pharmaceuticals utilizes glycyrrhetinic acid as an absorption enhancer. The composition comprises an effective amount of the pharmaceutically active substance, glycyrrhetinic acid, in an amount effective for enhancing permeation of the active substance across the nasal membrane, and a basic salt of an amino acid as an adjuvant. The composition may be administered to the nasal cavity in the form of a spray by using an atomizer, nebulizer, spayer, dropper or other device which ensures contact of the composition with the nasal mucus membrane.